Trade

with

CTI Biopharma Corp
(NASDAQ: CTIC)
AdChoices
2.29
-0.08
-3.38%
After Hours :
2.29
0.00
0.00%

Open

2.36

Previous Close

2.37

Volume (Avg)

528.25k (1.08M)

Day's Range

2.28-2.39

52Wk Range

1.60-4.25

Market Cap.

343.35M

Dividend Rate ( Yield )

-

Beta

1.19

Shares Outstanding

149.93M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 34.68M

    • Net Income

    • -42.74M

    • Market Cap.

    • 343.35M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -190.69

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.19

    • Forward P/E

    • -4.20

    • Price/Sales

    • 8.41

    • Price/Book Value

    • 36.63

    • Price/Cash flow

    • -7.24

      • EBITDA

      • -40.95M

      • Return on Capital %

      • -131.40

      • Return on Equity %

      • -1,241.06

      • Return on Assets %

      • -131.40

      • Book Value/Share

      • 0.06

      • Shares Outstanding

      • 149.93M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 5.25

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.53

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 338.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 24.85

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 98.91

            • 82.75

            • Pre-Tax Margin

            • -173.30

            • 39.38

            • Net Profit Margin

            • -190.69

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.00

              • 0.76

              • Current Ratio

              • 1.78

              • 2.92

              • Quick Ratio

              • 1.42

              • 2.35

              • Interest Coverage

              • -38.16

              • 38.02

              • Leverage Ratio

              • 5.90

              • 2.21

              • Book Value/Share

              • 0.06

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.60

                • 277.78

                • P/E Ratio 5-Year High

                • -80.90

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.87

                • 124.82

                • Price/Sales Ratio

                • 8.78

                • 9.35

                • Price/Book Value

                • 38.17

                • 8.50

                • Price/Cash Flow Ratio

                • -7.24

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -1,241.06

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -131.40

                    (-170.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -408.67

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 0.09

                  • 1.48

                  • Asset Turnover

                  • 0.69

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -41.53M
                  Operating Margin
                  -119.75
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.24
                  Ownership

                  Institutional Ownership

                  26.82%

                  Top 10 Institutions

                  21.00%

                  Mutual Fund Ownership

                  16.23%

                  Float

                  83.08%

                  5% / Insider Ownership

                  8.78%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • SPDR® S&P Biotech ETF

                  •  

                    4,036,549

                  • 0.00

                  • 2.54

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,928,123

                  • 0.00

                  • 1.98

                  • JNL/Eagle SmallCap Equity Fund

                  •  

                    2,498,625

                  • 0.00

                  • 1.67

                  • iShares Russell 2000 (AU)

                  •  

                    2,057,398

                  • -0.90

                  • 1.30

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,919,992

                  • 0.00

                  • 1.24

                  • Vanguard Extended Market Index Fund

                  •  

                    1,432,271

                  • 6.61

                  • 0.92

                  • iShares Russell 2000 Growth

                  •  

                    961,837

                  • -0.45

                  • 0.61

                  • AST Small-Cap Growth

                  •  

                    916,024

                  • 10.80

                  • 0.62

                  • MainStay VP Eagle Small Cap Growth Port

                  •  

                    746,331

                  • 8.26

                  • 0.50

                  • Candriam Eqs L Biotechnology

                  •  

                    710,000

                  • 24.56

                  • 0.48

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Eagle Asset Management, Inc.

                  •  

                    7,853,511

                  • +12.42%

                  • 5.05

                  • State Street Corp

                  •  

                    6,427,223

                  • -1.26%

                  • 4.31

                  • BlackRock Fund Advisors

                  •  

                    4,645,695

                  • +10.74%

                  • 3.11

                  • Vanguard Group, Inc.

                  •  

                    3,844,579

                  • +3.40%

                  • 2.58

                  • Fidelity Management and Research Company

                  •  

                    3,392,130

                  • -6.61%

                  • 2.27

                  • Government Pension Fund of Norway - Global

                  •  

                    1,911,373

                  • +648.63%

                  • 0.94

                  • Northern Trust Investments, N.A.

                  •  

                    1,486,123

                  • -11.52%

                  • 1.00

                  • JANE STREET GROUP, LLC

                  •  

                    1,011,235

                  • +47.17%

                  • 0.68

                  • Teachers Advisors, Inc.

                  •  

                    829,451

                  • +339.40%

                  • 0.56

                  • Geode Capital Management, LLC

                  •  

                    747,291

                  • +1.14%

                  • 0.50

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is...more primarily focused on commercializing PIXUVRI® (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May ...more2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies.The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.lessless

                  Key People

                  Dr. James A. Bianco,M.D.

                  CEO/Director/Founder/President

                  Dr. Phillip M. Nudelman,PhD

                  Chairman of the Board/Director

                  Dr. Jack W. Singer,M.D.

                  Chief Medical Officer/Director/Executive VP, Divisional/Founder/Other Executive Officer

                  Louis A. Bianco

                  CFO/Chief Accounting Officer/Executive VP, Divisional/Founder/Other Executive Officer

                  Dr. Matthew J. Plunkett, PhD

                  Executive VP, Divisional

                  • CTI Biopharma Corp

                  • 3101 Western Avenue

                  • Seattle, WA 98121

                  • USA.Map

                  • Phone: +1 206 282-7100

                  • Fax: +1 206 284-6206

                  • ctibiopharma.com

                  Incorporated

                  1991

                  Employees

                  106

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: